🏛️ Verified NIH Record • Updated 2026-08-12
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease (NCT05575037)
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease: MARINER
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Brigham and Women's Hospital
🩺 Plain-English Summary (8th-Grade Level)
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
Who can join: Review the eligibility criteria below.
Location: Brigham and Women's Hospital — Boston, Massachusetts
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Brigham and Women's Hospital — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Nasal Polyps
- Dupixent Study for Alternate Administration — Tacoma, Washington
- Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP — Charlottesville, Virginia
Explore by condition: All Nasal Polyps clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.